Notable examples of dual and pan-NR agonists include dual PPARα/γ agonists, such as saroglitazar and NET-144, which improve lipid profiles and insulin sensitivity, offering therapeutic benefits for conditions like T2DM, metabolic syndrome, and MASLD. Here, INS is linked to type 2 diabetes mellitus.